Regeneron Pharmaceuticals (REGN) Pushes Ahead In Weight Loss With Two Distinct Drug Bets

Simply Wall St.10-23

Regeneron Pharmaceuticals (NasdaqGS:REGN) reported progress on two obesity drug candidates, olatorepatide and trevogrumab, in October 2026. Internal data indicate olatorepatide is designed to improve ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2677910134?lang=en_US&edition=fundamental","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/company-cover/33715-card/1789122008118","is_english":true,"pubTime":"2026-10-23 12:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2677910134","market":"hk","top_or_hot":-1,"title":"Regeneron Pharmaceuticals (REGN) Pushes Ahead In Weight Loss With Two Distinct Drug Bets","media":"Simply Wall St.","content":"<div>\n<p>Regeneron Pharmaceuticals (NasdaqGS:REGN) reported progress on two obesity drug candidates, olatorepatide and trevogrumab, in October 2026. Internal data indicate olatorepatide is designed to improve ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-regn/regeneron-pharmaceuticals/news/regeneron-pharmaceuticals-regn-pushes-ahead-in-weight-loss-w\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Regeneron Pharmaceuticals (REGN) Pushes Ahead In Weight Loss With Two Distinct Drug Bets</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRegeneron Pharmaceuticals (REGN) Pushes Ahead In Weight Loss With Two Distinct Drug Bets\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-10-23 12:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-regn/regeneron-pharmaceuticals/news/regeneron-pharmaceuticals-regn-pushes-ahead-in-weight-loss-w><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Regeneron Pharmaceuticals (NasdaqGS:REGN) reported progress on two obesity drug candidates, olatorepatide and trevogrumab, in October 2026. Internal data indicate olatorepatide is designed to improve ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-regn/regeneron-pharmaceuticals/news/regeneron-pharmaceuticals-regn-pushes-ahead-in-weight-loss-w\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-regn/regeneron-pharmaceuticals/news/regeneron-pharmaceuticals-regn-pushes-ahead-in-weight-loss-w","article_id":"2677910134","we_media_id":null,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/company-cover/33715-card/1789122008118"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-regn/regeneron-pharmaceuticals/news/regeneron-pharmaceuticals-regn-pushes-ahead-in-weight-loss-w","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2677910134","pubTimestamp":1792730854,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Regeneron Pharmaceuticals (NasdaqGS:REGN) reported progress on two obesity drug candidates, olatorepatide and trevogrumab, in October 2026.\nInternal data indicate olatorepatide is designed to improve tolerability compared with existing weight loss treatments in development.\nTrevogrumab is being advanced with a focus on preserving lean body mass during weight loss, a key concern for clinicians.\nThe push behind olatorepatide and trevogrumab is only one part of the broader Regeneron story...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","LU2362541513.USD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (USD) ACC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU2023250504.SGD":"Allianz Thematica Cl AMg DIS H2-SGD","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU1917777945.USD":"安联专题基金Cl AT Acc","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU2362540622.SGD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (SGDHDG) ACC","IBB":"生物科技指数ETF-iShares Nasdaq","REGN":"再生元制药公司","IBBQ":"Invesco Nasdaq Biotechnology ETF","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","BBH":"VanEck Biotech ETF","BK4585":"ETF&股票定投概念","LU0882574055.USD":"富达全球健康医疗A ACC","BK4139":"生物科技","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","LU0823434583.USD":"BNP PARIBAS US GROWTH \"C\" (USD) ACC","LU2237438978.USD":"Amundi Funds US Pioneer A2 (C) USD","LU0058720904.USD":"联博国际健康护理基金A","LU0053666078.USD":"摩根大通基金-美国股票A（离岸）美元","LU0823434740.USD":"BNP PARIBAS US GROWTH \"C\" (USD) INC","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","TBXU":"Direxion Daily Biotech Top 5 Bull 2X ETF","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU2362541273.HKD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (HKD) ACC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC"},"translate_title":"再生元制药 (REGN) 通过两种不同的药物赌注推动减肥","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IBBQ":0.6,"REGN":1.5,"BBH":0.6,"IBB":0.6,"TBXU":0.6},"content_text":"Regeneron Pharmaceuticals (NasdaqGS:REGN) reported progress on two obesity drug candidates, olatorepatide and trevogrumab, in October 2026. Internal data indicate olatorepatide is designed to improve tolerability compared with existing weight loss treatments in development. Trevogrumab is being advanced with a focus on preserving lean body mass during weight loss, a key concern for clinicians. The push behind olatorepatide and trevogrumab is only one part of the broader Regeneron story investors may want to track. We have also flagged 2 other big wins for Regeneron Pharmaceuticals.  This push into obesity treatments is drawing attention, but it is only one angle on a wider set of healthcare exposures you can explore through 36 healthcare AI stocks. NasdaqGS:REGN Earnings & Revenue Growth as at Oct 2026 Regeneron Pharmaceuticals, a US biotech group with a reported market value of about $80.5b, already develops medicines across multiple disease areas. Moving into obesity care adds a new potential growth driver to its existing global drug development and manufacturing platform. Does the team leading Regeneron Pharmaceuticals have what it takes? See our full breakdown of the management team's track record and compensation. AdvertisementRegeneron’s obesity push leans into market size and differentiation For Regeneron Pharmaceuticals, these obesity candidates fit directly into the narrative that future earnings power depends on converting late stage programs into fresh revenue streams. A focus on improved tolerability for olatorepatide and lean mass preservation with trevogrumab targets two challenges in weight loss treatment that competitors are still working through. That keeps the obesity effort aligned with the catalyst of planned Phase III trials and broader cardiometabolic exposure, while leaving existing risks in retinal disease and Libtayo litigation unchanged. See how these catalysts shape Regeneron Pharmaceuticals' path to a $851 fair value. The key test from here is how Phase III olatorepatide data read out once those studies are running in 2026. Clear evidence on safety and real world discontinuation rates, compared with current weight loss options, would either support this differentiated obesity angle or weaken the case that Regeneron can build a meaningful second act in metabolic disease. The next check on Regeneron Pharmaceuticals is where the long range forecasts actually point Before you act on any single update, you would want to know where analysts expect this business to land a few years from now and how that trajectory reshapes the whole investment case. See where analysts expect Regeneron Pharmaceuticals to be in a few years. This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2677910134","isCrawlerRequest":true}